[{"address1": "171 Oyster Point Boulevard", "address2": "Suite 400", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 489 9000", "website": "https://www.surrozen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-\u00df, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig C. Parker M.B.A.", "age": 62, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 892375, "exercisedValue": 0, "unexercisedValue": 165332}, {"maxAge": 1, "name": "Mr. Charles  Williams", "age": 44, "title": "CFO, COO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 647639, "exercisedValue": 0, "unexercisedValue": 48919}, {"maxAge": 1, "name": "Dr. Li  Yang Ph.D.", "age": 55, "title": "Executive Vice President of Research", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 579850, "exercisedValue": 0, "unexercisedValue": 35138}, {"maxAge": 1, "name": "Dr. K. Christopher  Garcia Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roeland  Nusse Ph.D.", "age": 74, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1950, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Calvin  Kuo M.D., Ph.D.", "title": "Co-Founder & Member of Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel L. Chao M.D., Ph.D.", "title": "VP and Head of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Esther  Jhun", "title": "Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 12.4999, "open": 11.65, "dayLow": 11.5101, "dayHigh": 12.24, "regularMarketPreviousClose": 12.4999, "regularMarketOpen": 11.65, "regularMarketDayLow": 11.5101, "regularMarketDayHigh": 12.24, "payoutRatio": 0.0, "beta": 0.637, "forwardPE": -2.741573, "volume": 88554, "regularMarketVolume": 88554, "averageVolume": 28237, "averageVolume10days": 67140, "averageDailyVolume10Day": 67140, "bid": 11.71, "ask": 14.0, "bidSize": 1, "askSize": 3, "marketCap": 104558328, "fiftyTwoWeekLow": 5.9, "fiftyTwoWeekHigh": 18.17, "allTimeHigh": 210.0, "allTimeLow": 4.5, "priceToSalesTrailing12Months": 8.284472, "fiftyDayAverage": 12.83438, "twoHundredDayAverage": 10.688105, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 21682332, "profitMargins": -1.32295, "floatShares": 4798285, "sharesOutstanding": 8570355, "sharesShort": 113733, "sharesShortPriorMonth": 95161, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.013300001, "heldPercentInsiders": 0.04086, "heldPercentInstitutions": 0.71828, "shortRatio": 3.76, "shortPercentOfFloat": 0.015, "impliedSharesOutstanding": 8570355, "bookValue": 5.498, "priceToBook": 2.2189887, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -24263000, "trailingEps": -7.82, "forwardEps": -4.45, "lastSplitFactor": "1:15", "lastSplitDate": 1702512000, "enterpriseToRevenue": 1.718, "enterpriseToEbitda": -0.873, "52WeekChange": 0.2512821, "SandP52WeekChange": 0.12121439, "quoteType": "EQUITY", "currentPrice": 12.2, "targetHighPrice": 42.0, "targetLowPrice": 32.0, "targetMeanPrice": 37.0, "targetMedianPrice": 37.0, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 90390000, "totalCashPerShare": 10.547, "ebitda": -24833000, "totalDebt": 7514000, "quickRatio": 16.186, "currentRatio": 16.409, "totalRevenue": 12621000, "debtToEquity": 15.949, "revenuePerShare": 2.702, "returnOnAssets": -0.21933001, "returnOnEquity": -0.62799, "grossProfits": -8468000, "freeCashflow": -10652000, "operatingCashflow": -18663000, "grossMargins": -0.67095, "ebitdaMargins": -1.96759, "operatingMargins": -9.17294, "financialCurrency": "USD", "symbol": "SRZN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -2.3992195, "regularMarketPrice": 12.2, "marketState": "CLOSED", "postMarketChangePercent": -4.754098, "postMarketPrice": 11.62, "postMarketChange": -0.5799999, "regularMarketChange": -0.29990005, "regularMarketDayRange": "11.5101 - 12.24", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 28237, "fiftyTwoWeekLowChange": 6.2999997, "fiftyTwoWeekLowChangePercent": 1.0677966, "fiftyTwoWeekRange": "5.9 - 18.17", "fiftyTwoWeekHighChange": -5.9700003, "fiftyTwoWeekHighChangePercent": -0.32856357, "fiftyTwoWeekChangePercent": 25.12821, "earningsTimestampStart": 1746821116, "earningsTimestampEnd": 1746821116, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -7.82, "epsForward": -4.45, "fiftyDayAverageChange": -0.63438034, "fiftyDayAverageChangePercent": -0.049428202, "twoHundredDayAverageChange": 1.5118952, "twoHundredDayAverageChangePercent": 0.14145587, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-08-12", "prevName": "Consonance-HFW Acquisition Corp.", "nameChangeDate": "2025-11-07", "cryptoTradeable": false, "shortName": "Surrozen, Inc.", "longName": "Surrozen, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1610375400000, "corporateActions": [], "postMarketTime": 1762555061, "regularMarketTime": 1762549200, "exchange": "NCM", "messageBoardId": "finmb_401948183", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "Surrozen", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]